Literature DB >> 23371835

Purine nucleoside phosphorylase deficiency presenting as severe combined immune deficiency.

Raz Somech1, Atar Lev, Galia Grisaru-Soen, Shelly I Shiran, Amos J Simon, Eyal Grunebaum.   

Abstract

Purine nucleoside phosphorylase (PNP) deficiency is an autosomal recessive genetic disorder of the purine salvage pathway, associated with a variable extent of immunodeficiency. Here, we report a PNP-deficient patient who presented early in life with clinical and laboratory characteristics of severe combined immunodeficiency, including severe infections, marked T-and B-cell deficiency, lack of lymphocyte response to mitogenic stimulation, monoclonal T-cell receptors representation and the absence of T-cell receptor excision circles and Kappa-receptor excision circles. The patient carried homozygote mutation at the PNP gene that putatively led to aberrant splicing, allowing normal and abnormally spliced products from the mutant alleles. We suggest that the aberrant slice site was used preferentially over the normal slice site in some cells correlating with the severity of disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23371835     DOI: 10.1007/s12026-012-8380-9

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  19 in total

1.  Defining combined immunodeficiency.

Authors:  Chaim M Roifman; Raz Somech; Fotini Kavadas; Linda Pires; Amit Nahum; Ilan Dalal; Eyal Grunebaum
Journal:  J Allergy Clin Immunol       Date:  2012-06-02       Impact factor: 10.793

2.  Purine nucleoside phosphorylase deficiency: a new case report and identification of two novel mutations (Gly156A1a and Val217Ile), only one of which (Gly156A1a) is deleterious.

Authors:  Hamid Jack Moallem; Gladys Taningo; C K Jiang; Rochelle Hirschhorn; Senih Fikrig
Journal:  Clin Immunol       Date:  2002-10       Impact factor: 3.969

3.  Purine nucleoside phosphorylase deficiency: a mutation update.

Authors:  P L C Walker; Adele Corrigan; Monica Arenas; Emilia Escuredo; Lynette Fairbanks; Anthony Marinaki
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2011-12       Impact factor: 1.381

4.  Two novel mutations in a purine nucleoside phosphorylase (PNP)-deficient patient.

Authors:  I Dalal; E Grunebaum; A Cohen; C M Roifman
Journal:  Clin Genet       Date:  2001-06       Impact factor: 4.438

5.  Mutations in purine nucleoside phosphorylase deficiency.

Authors:  M L Markert; B D Finkel; T M McLaughlin; T J Watson; H R Collard; C P McMahon; L G Andrews; M J Barrett; F E Ward
Journal:  Hum Mutat       Date:  1997       Impact factor: 4.878

Review 6.  Purine nucleoside phosphorylase deficiency.

Authors:  M L Markert
Journal:  Immunodefic Rev       Date:  1991

7.  A novel mutation in purine nucleoside phosphorylase in a child with normal uric acid levels.

Authors:  B Al-Saud; O Alsmadi; S Al-Muhsen; A Al-Ghonaium; H Al-Dhekri; R Arnaout; M S Hershfield; H Al-Mousa
Journal:  Clin Biochem       Date:  2009-09-03       Impact factor: 3.281

8.  Purine nucleoside phosphorylase deficiency associated with a dysplastic marrow morphology.

Authors:  Yigal Dror; Eyal Grunebaum; Johann Hitzler; Aru Narendran; Charles Ye; Raymond Tellier; Vernon Edwards; Melvin H Freedman; Chaim M Roifman
Journal:  Pediatr Res       Date:  2004-01-07       Impact factor: 3.756

9.  Stroke in purine nucleoside phosphorylase deficiency.

Authors:  D A Tam; R T Leshner
Journal:  Pediatr Neurol       Date:  1995-02       Impact factor: 3.372

10.  The kinetics of early T and B cell immune recovery after bone marrow transplantation in RAG-2-deficient SCID patients.

Authors:  Atar Lev; Amos J Simon; Mor Bareket; Bella Bielorai; Daphna Hutt; Ninette Amariglio; Gideon Rechavi; Raz Somech
Journal:  PLoS One       Date:  2012-01-25       Impact factor: 3.240

View more
  8 in total

1.  Novel Genetic Mutations in the First Swedish Patient with Purine Nucleoside Phosphorylase Deficiency and Clinical Outcome After Hematopoietic Stem Cell Transplantation with HLA-Matched Unrelated Donor.

Authors:  Nicholas Brodszki; Maria Svensson; André B P van Kuilenburg; Judith Meijer; Lida Zoetekouw; Lennart Truedsson; Jacek Toporski
Journal:  JIMD Rep       Date:  2015-05-13

Review 2.  Inborn errors of metabolism underlying primary immunodeficiencies.

Authors:  Nima Parvaneh; Pierre Quartier; Parastoo Rostami; Jean-Laurent Casanova; Pascale de Lonlay
Journal:  J Clin Immunol       Date:  2014-08-01       Impact factor: 8.317

3.  The Broad Clinical Spectrum and Transplant Results of PNP Deficiency.

Authors:  Polina Stepensky; Irina Zaidman; Yael Dinur Schejter; Ehud Even-Or; Bella Shadur; Adeeb NaserEddin
Journal:  J Clin Immunol       Date:  2019-11-09       Impact factor: 8.542

4.  An NMF-Based Methodology for Selecting Biomarkers in the Landscape of Genes of Heterogeneous Cancer-Associated Fibroblast Populations.

Authors:  Flavia Esposito; Angelina Boccarelli; Nicoletta Del Buono
Journal:  Bioinform Biol Insights       Date:  2020-05-08

5.  Expanding the drug discovery space with predicted metabolite-target interactions.

Authors:  Andrea Nuzzo; Somdutta Saha; Ellen Berg; Channa Jayawickreme; Joel Tocker; James R Brown
Journal:  Commun Biol       Date:  2021-03-05

6.  Combined Transcriptomics, Proteomics and Bioinformatics Identify Drug Targets in Spinal Cord Injury.

Authors:  Jure Tica; Elizabeth J Bradbury; Athanasios Didangelos
Journal:  Int J Mol Sci       Date:  2018-05-14       Impact factor: 5.923

7.  Partial Purine Nucleoside Phosphorylase Deficiency Helps Determine Minimal Activity Required for Immune and Neurological Development.

Authors:  Eyal Grunebaum; Nicholas Campbell; Matilde Leon-Ponte; Xiaobai Xu; Hugo Chapdelaine
Journal:  Front Immunol       Date:  2020-06-30       Impact factor: 7.561

Review 8.  Inborn errors of immunity associated with characteristic phenotypes.

Authors:  Maine Luellah Demaret Bardou; Marina Teixeira Henriques; Anete Sevciovic Grumach
Journal:  J Pediatr (Rio J)       Date:  2020-12-19       Impact factor: 2.990

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.